SATELLITE SYMPOSIA SCHEDULE and AGENDA (as of May 15, 2017)

Tuesday, June 13, 2017

12:00 – 14:00  2 parallel symposia

Room BI  CELLTRION HEALTHCARE
THE 1ST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE
Chair: C. Buske, Ulm (Germany)

12:00 – 12:20  WELCOME AND INTRODUCTION: PERCEPTUAL EVOLUTION ON BIOSIMILAR
C. Buske, Ulm (Germany)

12:20 – 12:40  REDUCING BUDGETS, INCREASING ACCESS
L. Gulácsi, Budapest (Hungary)

12:40 – 13:10  THE RATIONALE OF BIOSIMILARITY
J. Gonçalves, Lisboa (Portugal)

13:10 – 13:40  CLINICAL EVIDENCE OF BIOSIMILAR RITUXIMAB
W.S. Kim, Seoul (South Korea)

13:40 – 14:00  BIOSIMILAR IN ONCOLOGY: YESTERDAY, TODAY AND A LOOK AHEAD
Panel Discussion

Room BII  NOVARTIS PHARMACEUTICALS CORPORATION
CHALLENGES AND OPPORTUNITIES IN THE MANAGEMENT OF AGGRESSIVE
B CELL LYMPHOMAS
Chair: S.J. Schuster, Philadelphia, PA (USA)

12:00 – 12:05  OPENING REMARKS BY THE CHAIR

12:05 – 12:35  NOVEL APPROACHES IN THE ALGORITHM FOR MANAGEMENT OF AGGRESSIVE
B CELL LYMPHOMAS
P. Borchmann, Cologne (Germany)

12:35 – 13:05  AGGRESSIVE B CELL LYMPHOMAS: THE ROLE OF STEM CELL TRANSPLANT IN
THE ERA OF TARGETED THERAPIES
A. Sureda, Barcelona (Spain)

13:05 – 13:35  EXPERIENCES FROM THE USE OF INVESTIGATIONAL CAR T CELL THERAPIES IN
B CELL LYMPHOMAS
S.J. Schuster, Philadelphia, PA (USA)

13:35 – 14:00  PANEL DISCUSSION
15:30 – 17:30  3 parallel symposia

Room A  GILEAD SCIENCES
ADVANCING PROGNOSTICATION AND TARGETED STRATEGIES IN CLL AND FL
Co-chairs: M. Ghielmini, Bellinzona (Switzerland) and M. Hallek, Cologne (Germany)

15:30 – 15:35  WELCOME AND INTRODUCTION
M. Ghielmini, Bellinzona (Switzerland)

15:35 – 15:50  DECIPHERING THE MOLECULAR LANDSCAPE IN CLL: NEW TREATMENT CHALLENGES
D. Rossi, Bellinzona (Switzerland)

15:50 – 16:05  UNTANGLING THE COMPLEXITIES OF FL: CURRENT TREATMENT CHALLENGES
A. Davies, Southampton (UK)

16:05 – 16:20  HIGH RISK VERSUS LOW RISK IN FL: PROGNOSTICATION FOR A PRECISION APPROACH
B. Kahl, Saint Louis (USA)

16:20 – 16:30  CROSS-TALK: SIMILARITIES AND DIFFERENCES IN APPROACHES TO RISK STRATIFICATION AND TREATMENT IN CLL AND FL
Led by M. Ghielmini, Bellinzona (Switzerland)

16:30 – 16:50  HITTING THE RIGHT TARGETS IN CLL AND FL: FROM PATHWAY TO PRACTICE
M. Hallek, Cologne (Germany) and M. Ghielmini, Bellinzona (Switzerland)

16:50 – 17:05  TARGETED TREATMENTS IN CLL AND FL: SEQUENCING OR COMBINATIONS?
A. Zelenetz, New York, NY (USA)

17:05 – 17:25  CROSS-TALK: MAKING INFORMED TREATMENT CHOICES IN CLL AND FL
Led by M. Hallek, Cologne (Germany)

17:25 – 17:30  SUMMARY AND CLOSE
M. Hallek, Cologne (Germany)

Room B  BRISTOL-MYERS SQUIBB
IMMUNO-ONCOLOGY RESEARCH IN LYMPHOMA: PRESENT AND FUTURE
Chair: G. Collins, Oxford (UK)

15:30 – 15:35  WELCOMING REMARKS
G. Collins, Oxford (UK)

15:35 – 15:55  LYMPHOMA IN REVIEW: CHALLENGES IN TODAY’S CLINICAL PRACTICE
G. Collins, Oxford (UK)

15:55 – 16:15  ONGOING EXPLORATIONS OF IMMUNO-ONCOLOGY IN CLASSICAL HODGKIN LYMPHOMA
P. Brice, Paris (France)

16:15 – 16:35  PURSUING EXISTING NEEDS THROUGH INVESTIGATIONS IN NON-HODGKIN LYMPHOMA: IMMUNO-ONCOLOGY AND MORE
T.M. Illidge, Manchester (UK)

16:35 – 16:55  LIGHTING THE WAY: INFORMING LYMPHOMA PATHOLOGY WITH BIOMARKER RESEARCH
D. de Jong, Amsterdam (The Netherlands)
16:55 – 17:25 OPEN DISCUSSION WITH THE EXPERTS
All

CLOSING REMARKS
Moderated by G. Collins, Oxford (UK)

Room B II SERVIER ONCOLOGY
MANAGEMENT OF MULTIPLY RELAPSED AGGRESSIVE NHL: NEW PERSPECTIVES
Co-chairs: R. Pettengell, London (UK) and E. Van Den Neste, Brussels (Belgium)

15:30 - 15:35 INTRODUCTION
E. Van Den Neste, Brussels (Belgium)

15:35 – 15:55 TREATMENT LANDSCAPE OF B-CELL-NHL PATIENTS, LOOKING INTO THE FUTURE OF NEW STRATEGIES
P.L. Zinzani, Bologna (Italy)

15:55 – 16:10 PATIENTS WITH RELAPSED DLBCL WHO FAIL SECOND-LINE SALVAGE THERAPY: MONOTHERAPY VERSUS COMBINATION THERAPY
E. Van Den Neste, Brussels (Belgium)

16:10 – 16:25 PIXANTRONE FOR THIRD- AND FOURTH-LINE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN B-CELL LYMPHOMA
R. Pettengell, London (UK)

16:25 – 16:55 PATIENT CASE 1 – A. Hayat, Galway (Ireland)
PATIENT CASE 2 – K. Hübel, Cologne (Germany)

16:55 – 17:15 PANEL DISCUSSION
All Faculty

17:15 – 17:20 CONCLUSION
R. Pettengell, London (UK)

19:00 – 21:00 3 parallel symposia

Room A ROCHE
IMPROVING TREATMENT STRATEGIES FOR PATIENTS WITH FOLLICULAR LYMPHOMA: HOW TO TRANSLATE NOVEL STUDY DATA INTO CLINICAL PRACTICE
Chair: B.D. Cheson, Washington D.C. (USA)

19:00 – 19:10 WELCOME AND INTRODUCTION
B.D. Cheson, Washington D.C. (USA)

19:10 – 19:35 THE PATIENTS’ PERSPECTIVE AND QUALITY OF LIFE IN FOLLICULAR LYMPHOMA
R. Pfau, Aesch (Switzerland)

19:35 – 20:00 HOW CAN WE IMPROVE FIRST-LINE TREATMENT FOR FOLLICULAR LYMPHOMA AND HOW TO MEASURE IMPROVEMENT?
M. Rummel, Giessen (Germany)

20:00 – 20:25 RECENT ADVANCES IN TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA
A. Davies, Southampton (UK)

20:25 – 20:50 MANAGEMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA IN THE FUTURE
Room B I  

**BAYER**  
**SHIFTING PARADIGMS IN THE MANAGEMENT AND TREATMENT OF INDOLENT NHL**  
Co-chairs: M. Ghielmini, Bellinzona (Switzerland) and M. Dreyling, Munich (Germany)

**WELCOME**
M. Ghielmini, Bellinzona (Switzerland) and M. Dreyling, Munich (Germany)

**DIFFERENTIAL BIOLOGY OF PI3K INHIBITORS IN NHL**
G. Lenz, Muenster (Germany)

**EMERGING CHEMO-FREE TREATMENT STRATEGIES IN INDOLENT NHL**
J.P. Leonard, New York, NY (USA)

**CLINICAL EXPERIENCE WITH COPANLISIB IN RELAPSED/REFRACTORY INDOLENT LYMPHOMA**
G. Follows, Cambridge (UK)

**PANEL DISCUSSION/Q&A**
M. Ghielmini, Bellinzona (Switzerland) and M. Dreyling, Munich (Germany)

*Copanlisib is an investigational agent currently in clinical trials and is not approved by Swissmedic, the FDA, EMA, or other health authorities. The efficacy and safety of copanlisib have not been established. / Bayer (Schweiz) AG, Grubenstrasse 6, 8045 Zurich, Switzerland*

---

Room B II  

**TAKEDA ONCOLOGY**  
**TARGETING CD30 IN LYMPHOMA: A MARKER FOR CHANGE?**
Co-chairs: A. Engert, Cologne (Germany) and K.J. Savage, Vancouver (Canada)

19:00 – 19:05  
**WELCOME AND INTRODUCTIONS**
A. Engert, Cologne (Germany) and K.J. Savage, Vancouver (Canada)

19:05 – 19:25  
**CD30: FROM DIAGNOSTIC MARKER TO THERAPEUTIC TARGET**
**PANEL DISCUSSION: ROLE OF CD30**
A. Engert, Cologne (Germany) and K.J. Savage, Vancouver (Canada)

19:25 – 19:45  
**DIRECTING TREATMENT TO CD30-DEFINED MALIGNANCIES: A FOCUS ON RELAPSED/REFRACTORY HODGKIN LYMPHOMA**
A. Sureda, Barcelona (Spain)

19:45 – 20:05  
**BEYOND THE RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENT: WHAT ARE OUR OPTIONS IN THE FRONTLINE SETTING?**
A. Engert, Cologne (Germany)

20:05 – 20:25  
**CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA**
K.J. Savage, Vancouver (Canada)

20:25 – 20:45  
**CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA**
S. Horwitz, New York, NY (USA)

20:45 – 20:55  
**PANEL DISCUSSION / Q&A SESSION: HOW I TREAT CD30-POSITIVE LYMPHOMA**
All, led by A. Engert, Cologne (Germany) and K.J. Savage, Vancouver (Canada)
Wednesday, June 14, 2017

19:00 – 21:00 2 parallel symposia

Room A  JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
CURRENT CONTROVERSIES IN B-CELL LYMPHOMAS: HOW TO MANAGE PATIENTS WITH HIGH UNMET NEEDS
Chair: M. Ghielmini, Bellinzona (Switzerland)

19:00 – 19:10 WELCOME AND INTRODUCTION
M. Ghielmini, Bellinzona (Switzerland)

19:10 – 19:35 CURRENT DILEMMAS IN DIFFUSE LARGE B-CELL LYMPHOMA
G. Lenz, Berlin (Germany)

19:35 – 19:55 CLINICAL COMPLEXITIES IN MANTLE CELL LYMPHOMA
S. Rule, Plymouth (UK)

19:55 – 20:15 CHALLENGING CASES IN FOLLICULAR LYMPHOMA
C. Buske, Ulm (Germany)

20:15 – 20:30 NEW OPTIONS IN THE MANAGEMENT OF MARGINAL ZONE LYMPHOMA
C. Thieblemont, Paris (France)

20:30 – 20:45 WALDENSTRÖM’S MACROGLOBULINEMIA – WHERE NEXT?
S. Treon, Boston MA (USA)

20:45 – 21:00 PANEL DISCUSSION AND CLOSING REMARKS
M. Ghielmini, Bellinzona (Switzerland) and all faculty

Room B  ABBVIE, INC.
NOVEL TREATMENTS IN RELAPSED/REFRACTORY CLL: PRESENT AND FUTURE
Chair: U. Jäger, Vienna (Austria)

19:00 – 19:05 CHAIR’S WELCOME AND INTRODUCTION
U. Jäger, Vienna (Austria)

19:05 – 19:15 SETTING THE SCENE: THE BURDEN OF RELAPSED/REFRACTORY CLL
U. Jäger, Vienna (Austria)

19:15 – 19:35 HISTORICAL PERSPECTIVES ON RELAPSED/REFRACTORY CLL THERAPY
D. Rossi, Bellinzona (Switzerland)

19:35 – 20:00 CURRENT TARGETED TREATMENT OPTIONS IN RELAPSED/REFRACTORY CLL
B. Eichhorst, Cologne (Germany)

20:00 – 20:20 NEW AGENTS IN DEVELOPMENT: INNOVATIONS IN RELAPSED/REFRACTORY CLL
V. Leblond, Paris (France)

20:20 – 20:45 ROUNDTABLE DISCUSSIONS
All

20:45 – 20:55 AUDIENCE Q&A
### Thursday, June 15, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:00 – 21:00</td>
<td>2 parallel symposia</td>
</tr>
<tr>
<td>Room A</td>
<td><strong>CELGENE</strong></td>
</tr>
<tr>
<td></td>
<td>MANAGEMENT OF B-CELL NON-HODGKIN LYMPHOMA: WHERE ARE WE NOW AND WHERE ARE WE GOING? Chair: G. Salles, Lyon (France)</td>
</tr>
<tr>
<td>19:00 – 19:10</td>
<td>WELCOME AND INTRODUCTION</td>
</tr>
<tr>
<td></td>
<td>G. Salles, Lyon (France)</td>
</tr>
<tr>
<td>19:10 – 19:30</td>
<td>HURDLES AND UNMET NEEDS IN THE MANAGEMENT OF INDOLENT NHL</td>
</tr>
<tr>
<td></td>
<td>G. Salles, Lyon (France)</td>
</tr>
<tr>
<td>19:30 – 19:50</td>
<td>PROGRESS AND PROMISE: CURRENT AND FUTURE PERSPECTIVES ON THERAPY OF INDOLENT NHL</td>
</tr>
<tr>
<td></td>
<td>N.H. Fowler, Houston, TX (USA)</td>
</tr>
<tr>
<td>19:50 – 20:00</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td></td>
<td>All Faculty</td>
</tr>
<tr>
<td>20:00 – 20:20</td>
<td>IMPROVING FRONTLINE TREATMENT OUTCOMES IN DLBCL</td>
</tr>
<tr>
<td></td>
<td>U. Vitolo, Turin (Italy)</td>
</tr>
<tr>
<td>20:20 – 20:40</td>
<td>NEXT GENERATION THERAPIES IN B-CELL NHL: THE ROLE OF PROTEIN HOMEOSTASIS</td>
</tr>
<tr>
<td></td>
<td>A. Gandhi, Summit, NJ (USA)</td>
</tr>
<tr>
<td>20:40 – 20:50</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td></td>
<td>All Faculty</td>
</tr>
<tr>
<td>20:50 – 21:00</td>
<td>CONCLUDING REMARKS</td>
</tr>
<tr>
<td></td>
<td>G. Salles, Lyon (France)</td>
</tr>
</tbody>
</table>

**Room B**

MUNDIPHARMA MEDICAL COMPANY - TEVA ONCOLOGY

CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?

Chair: M. Ghielmini, Bellinzona (Switzerland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:00 – 19:05</td>
<td>WELCOME AND INTRODUCTION</td>
</tr>
<tr>
<td></td>
<td>M. Ghielmini, Bellinzona (Switzerland)</td>
</tr>
<tr>
<td>19:05 – 19:25</td>
<td>THE ROLE OF INDUCTION CHEMOTHERAPY FOR THE EFFICACY OF MAINTENANCE IN FOLLICULAR LYMPHOMA</td>
</tr>
<tr>
<td></td>
<td>M. Dreyling, Munich (Germany)</td>
</tr>
<tr>
<td>19:25 – 19:45</td>
<td>CAN WE FORESEE A CHEMO-FREE TREATMENT FOR FOLLICULAR LYMPHOMA?</td>
</tr>
<tr>
<td></td>
<td>M. Ghielmini, Bellinzona (Switzerland)</td>
</tr>
<tr>
<td>19:45 – 20:00</td>
<td>ROUNDTABLE DISCUSSION</td>
</tr>
<tr>
<td></td>
<td>All Faculty</td>
</tr>
<tr>
<td>20:00 – 20:20</td>
<td>CAN WE FORESEE A CHEMO-FREE TREATMENT FOR CHRONIC LYMPHOCYTIC</td>
</tr>
</tbody>
</table>
LEUKEMIA?
D.M. Brander, Durham, NC (USA)

20:20 – 20:40 NEW CHEMOTHERAPEUTIC AGENTS FOR LYMPHOMA
O. O’Connor, New York, NY (USA)

20:40 – 20:55 ROUNDTABLE DISCUSSION
All Faculty

20:55 – 21:00 CONCLUSION AND CLOSURE
M. Ghielmini, Bellinzona (Switzerland)

Friday, June 16, 2017

Room A
18:30 – 19:30 ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND – IOSI
“THE BIG DEBATE: POINT COUNTER POINT”
HAVE NEW DRUGS MADE STEM CELL TRANSPLANTATION OBSOLETE?
Chair: M. Ghielmini, Bellinzona (Switzerland)
Supported by Gilead Sciences Europe Ltd who provided funding.

- CLL: yes: J.G. Gribben, London (UK) vs no: D.G. Maloney, Seattle, WA (USA)
- HL: yes: P. Borchmann, Cologne (Germany) vs no: A. Sureda, Barcelona (Spain)
- FL: yes: J.P. Leonard, New York, NY (USA) vs no: S. Montoto, London (UK)

Room B
18:45 – 20:45 KITE PHARMA
ENGINEERED T-CELL THERAPY: CAR-T’S ESTABLISHING A NEW PARADIGM OF TREATMENT IN RELAPSED AND REFRACTORY NHL?
Chair: G. Salles, Lyon (France)
Co-chair: P. Dreger, Heidelberg (Germany)

18:45 – 19:00 INTRODUCTION AND A REVIEW OF THE CURRENT RELAPSED AND REFRACTORY NHL LANDSCAPE
G. Salles, Lyon (France)

19:00 – 19:30 THE IMMUNE SYSTEM, T-CELL BIOLOGY AND THE RATIONALE FOR CAR-T THERAPY
J.G. Gribben, London (UK)

19:30 – 19:55 THE DEVELOPMENT OF KTE-C19, THE FIRST CAR-T DEVELOPED FOR R/R NHL – A REVIEW OF FULL DEVELOPMENT THROUGH TO THE ZUMA-1 FINAL ANALYSIS
S. Neelapu, Houston, TX (USA)

19:55 – 20:20 PREPARING THE CENTERS TO MANAGE CAR-T PATIENTS
M.J. Kersten, Amsterdam (The Netherlands)

20:20 – 20:40 ROUNDTABLE Q&A SESSION

20:40 – 20:45 CLOSING REMARKS
P. Dreger, Heidelberg (Germany)